Working... Menu
Trial record 68 of 1269 for:    IFNA2

Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT01442779
Recruitment Status : Completed
First Posted : September 29, 2011
Results First Posted : September 29, 2011
Last Update Posted : April 20, 2012
Amarillo Biosciences, Inc.
Information provided by (Responsible Party):
Texas Tech University Health Sciences Center

Brief Summary:
The purpose of this study is to determine the possible efficacy of low dose, orally administered interferon alpha in subjects with Idiopathic Pulmonary Fibrosis (IPF).

Condition or disease Intervention/treatment Phase
Respiratory Tract Diseases Lung Diseases Lung Diseases, Interstitial Pulmonary Fibrosis Drug: Interferon alpha oral lozenge Phase 2

Detailed Description:

This is a pilot study to determine if oral administration of low doses of Interferon alpha might be effective in treating Idiopathic Pulmonary Fibrosis (IPF). This is a disease that damages the lungs leading to marked decreases in the quality of life and death within 3-5 years after diagnosis. The cause is unknown. The standard treatment has for some time been steroids such as prednisone or prednisolone because of their anti-inflammatory actions, but there is little evidence that steroids either improve the condition, prevent further deterioration or improve life expectancy. Additionally, they have many side effects.

In this disease, normal cells are damaged for unknown reasons and replaced by a type of scar. This scar tissue prevents the easy movement of oxygen from the lungs into the blood, making it difficult for the patient to perform normal activities. With progression, which usually occurs rapidly, patients require supplemental oxygen to perform even simple tasks.

Interferons are chemicals normally produced in the body and the rate of their production has been shown to be reduced in the lungs of patients with IPF. They are involved in regulating the activity of the immune system which may play a role in initiating the damage to the lungs in IPF and they also can inhibit the activity of the cells that form the scar tissue. Our hypothesis is that treating patients with interferon might prevent damage to additional normal tissue and prevent the formation of additional scar tissue. This would prevent progression, improve the quality of life and extend the expected life span if successful. Another study has been ongoing in which IPF patients have been given injections of large doses of another type of interferon. This treatment regimen is expensive and side effects have been fairly frequent.

In contrast, we are treating IPF patients with low doses of interferon administered orally. The interferon is taken three times per day by letting a lozenge dissolve in the mouth. These low doses have been shown to produce effects in patients with other diseases and they produce very few side effects. If side effects occur, they usually are not severe and go away quickly. Those reported most commonly by other subjects have been headaches, nausea, rashes, respiratory infections, sore throat or diarrhea. No one has had to stop taking the medicine because of the side effects. The medicine is provided free of charge.

This study has been going on for about 5 years. The subjects are given the same tests that they receive as part of their standard of care. These include chest x-rays, High Resolution CT scans, pulmonary function tests and some blood tests. They are done before starting interferon alpha, and, depending on the test, are repeated at 3-, 6-, 9- or 12 month intervals. In addition subjects are asked to complete questionnaires on the quality of life, cough history and a dyspnea index at each visit.

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Actual Enrollment : 18 participants
Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Clinical Trial of Low Dose Oral Interferon Alpha in Idiopathic Pulmonary Fibrosis
Study Start Date : September 2000
Actual Primary Completion Date : May 2007
Actual Study Completion Date : May 2007

Intervention Details:
  • Drug: Interferon alpha oral lozenge
    dose form - oral lozenge dose - 150 International Units (IU) frequency - 3 times a day duration - at least 1 year

Primary Outcome Measures :
  1. Minimal/no Progression (1 yr) by High Resolution Computed Tomography (HRCT) & Pulmonary Function [ Time Frame: 1 yr ]
    Disease progression was determined by comparing results of the High Resolution Computed Tomography(HRCT) and pulmonary function at one year to the baseline HRCT & pulmonary function. The same radiologist did the comparsion for all subjects.

  2. Minimal/no Change in Quality of Life [ Time Frame: 12 months ]

Secondary Outcome Measures :
  1. Participants With Change in Cough [ Time Frame: 1 month ]
    changes in cough status after treatment for 1 month.

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   50 Years and older   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • The only subjects to be included in this study are those diagnosed with Idiopathic Pulmonary Fibrosis with diagnosis based on the criteria published by the American Thoracic Society in the International Consensus Statement.

    1. Exclusion of other known causes of interstitial lung disease.
    2. Abnormal pulmonary function studies.
    3. Bibasilar reticular abnormalities with minimal ground glass opacities on HRCT scan.
    4. Biopsy or lavage showing no features supporting alternative diagnosis.
    5. Patient older than 50 years of age.
    6. Insidious onset of otherwise unexplained dyspnea on exertion.
    7. Duration greater than 3 months.
    8. Bibasilar, inspiratory crackles.

Exclusion Criteria:

  • under the age of 50
  • history of hypersensitivity to interferons
  • history of hypersensitivity to biological products such as vaccines
  • pregnant or lactating women
  • women of child bearing age not pregnancy protected during the study
  • unresolved serious cardiovascular disease

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT01442779

Layout table for location information
United States, Texas
Texas Tech University Health Sciences Center
Lubbock, Texas, United States, 79430
Sponsors and Collaborators
Texas Tech University Health Sciences Center
Amarillo Biosciences, Inc.
Layout table for investigator information
Principal Investigator: Cynthia Jumper, MD Texas Tech University Health Sciences Center

Layout table for additonal information
Responsible Party: Texas Tech University Health Sciences Center Identifier: NCT01442779     History of Changes
Other Study ID Numbers: 00190
First Posted: September 29, 2011    Key Record Dates
Results First Posted: September 29, 2011
Last Update Posted: April 20, 2012
Last Verified: April 2012

Keywords provided by Texas Tech University Health Sciences Center:
Idiopathic Pulmonary Fibrosis
Interferon alpha

Additional relevant MeSH terms:
Layout table for MeSH terms
Interferon alpha-2
Lung Diseases
Pulmonary Fibrosis
Idiopathic Pulmonary Fibrosis
Idiopathic Interstitial Pneumonias
Respiratory Tract Diseases
Lung Diseases, Interstitial
Pathologic Processes
Antineoplastic Agents
Antiviral Agents
Anti-Infective Agents
Immunologic Factors
Physiological Effects of Drugs